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Long-term treatment results
of Polish pediatric and
adolescent patients enrolled
in the ALL IC-BFM 2002 trial
To the Editor:
In 2002, the Polish Pediatric Leukemia/Lymphoma Study Group
joined the ALL IC-BFM 2002 trial, which was intended for countries
with inadequate skills and resources for PCR-based MRD monitoring.1
On the basis of the pioneering findings of the BFM group regarding
measurement of early response to prednisone in peripheral blood on
day eight and percentage of bone marrow blasts on day 15, all the
patients could be stratified in risk groups by accessible and inexpen-
sive methods. Considering inequalities in resources and facilities
among the participating countries, it seems justified to us to report on
the treatment results of this trial in patients with ALL treated in
14 Polish pediatric oncohematology center.
Between November 2002 and November 2011, 1872 children aged
1-17 with newly diagnosed ALL were consecutively enrolled in the ALL
IC-BFM 2002 protocol according to a registered trial at ClinicalTrials.gov
(NCT00764907). Infants younger than 12 months were excluded. The
patients were diagnosed according to cytomorphologic criteria (more
than 25% lymphoblasts present in bone marrow), immunophenotyping
(EGIL criteria) and cytogenetic and FISH/molecular genetics examination
of bone marrow specimens. A central review on the national level of
morphologic, flow cytometric and genetic results was required. The prog-
nostic factors of ALL IC-BFM 2002 included: age, white blood cell count
(WBC) at diagnosis, response to prednisone at day 8, results of bone
marrow evaluation on day 15 or 33 of the therapy and, finally, the pres-
ence of BCR/ABL1, and KMT2A/AFF1 specific genetic aberrations. At
diagnosis, the patients were stratified into three groups: standard, inter-
mediate, and high-risk groups. Risk group definitions and treatment plan
are presented in the paper by Stary et al.1 OS and EFS curves were esti-
mated according to Kaplan-Meier with Greenwood Standard Error (SE),
and compared using a two-tailed log-rank test. Cumulative incidence
(CI) curves for the events were estimated according to risk groups, and
were compared using the Gray test. All statistical calculations were per-
formed using STATISTICA13. The study was approved by the local insti-
tutional review board and a written informed consent from the
guardians was a prerequisite.
A total of 1872 patients (56.6% males and 43.4% females) were
treated under the ALL IC-BFM 2002 Protocol. A median follow up
time for the entire group was 6.4 years (Q1 = 4.32, Q3 = 8.53). The
median age at diagnosis was 5.3 years, ranging from more than 1 to
17 years of age. Most children (55%) were in the age range 1 to
<6 years, while the group aged 6 to <10 years accounts for 19% of
the cohort, 10 to <15 years was 17%, and those older than 15 years
constitute 9%. For WBC counts at diagnosis below 20×109/l was rev-
ealed in 64.3% of the children while in 10.1% WBC was more than
100×109/l. CNS status 1 in 88%, 2-7% and 5% showed signs of CNS
involvement. Mediastinal involvement from the leukemic process was
found in 7.8%, testicular involvement was shown in 20 boys (1.9%).
The immunophenotype in most children was revealed as preB cell lin-
eage (89%) and T cell lineage was shown in 11%. The conventional
cytogenetic analysis was performed in all subjects with newly diag-
nosed ALL. Chromosome preparations of BM cells were informative
for analysis in 1056 (56.4%) patients. Chromosome aberrations were
revealed in 523 (27.9%) cases. Hypodiploidy was presented in
22 (2.1%) patients. Investigations in fusion genes BCR/ABL1,
KMT2A/AFF1 were required under the ALL IC-BFM 2002 protocol as
primary and obligatory tests. The t (9;22)(q34;q11.2) translocation
that produced the fusion gene BCR/ABL1 was detected in 65 (3.5%)
pediatric patients. The rearrangements of KMT2A were presented in
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42 (2.2%) children and in five children the KMT2A/AFF1 fusion gene
was confirmed.
According to risk stratification, 32.6% of the children were quali-
fied for a standard-risk group (SR), 48.1% were qualified as
intermediate-risk (IR), and 19.3% as high-risk (HR). After 7 days of ste-
roid therapy, 10.9% of patients were assessed as prednisone poor
responders. Bone marrow on day 15 M1 (<5% blasts) was revealed in
68.6%, on M2 (5 ≥ to <25% blasts) in 19.7%, and on M3 (≥25% blasts)
in 9.9% patients. Complete remission (CR1) of the disease on day
33 was achieved in 96% of the patients, while 65 patients (4%)
achieved CR1 between days 52-96, and were classified as late
responders and they were stratified to the HR group. Five children did
not achieve CR1 by day 96 (before first HR2 block) and they contin-
ued therapy on individual decisions.
A total of 268 (14.3%) deaths were noted in the entire group,
including 30 (11.2%) deaths in the SR group, 116 (43.2%) in IR, and
122 (45.5%) deaths in HR. Given the size of the risk groups, the death
rate observed in the SR group was 4.77%, 13.47% in IR, and 32.87%
in the HR group. When patients who underwent BMT are excluded,
the death rate in the HR group is as high as 39.3%. Cumulative death
risk in the SR group at 5 years was estimated at 4.4%, 14.2% in the IR
group, and 37.3% in HR (Figure S1). In 36 cases, deaths happened dur-
ing the induction therapy, before CR1 was achieved, and the esti-
mated death rate at induction was 1.92% (0.82% for the SR group,
2.23% for IR, and 3.04% for the HR group). A total of 81 deaths were
noted at the CR1 phase (death rate of 4.55%, with 1.19% in SR,
3.26% in IR, and 13.77% in the HR group). Deaths related to relapse
were noted in 106 children.
The incidence of death at CR was significantly higher in children
aged ≥10 years vs younger children (9.3% vs 2.6%; P < .001) and in T-
ALL vs BCP-ALL (9% v 3.5%; P < .001). But, differences were not
found between girls and boys (4.0% v 4.5%; P = .7). The main causes
of deaths are presented in Table S1.
Overall survival (OS) for 1872 children with ALL treated under the
ALL IC-BFM 2002 protocol in Poland was 86% after 5 years, whereas
the EFS rate was 79%. The EFS for the SR group (n = 608) was 90%,
80% for IR (n = 899), and 62% for HR (n = 361) at 5 years, and at
10 years EFS was 88%, 79%, and 59%, respectively (Figure 1).
Relapses occurred in 275 children (14.7%), of which 51 cases
occurred in the SR group (8.4% of the patients who were stratified for
the SR group), 147 cases in IR (16.4%), and 77 in HR (21.2%). Cumula-
tive relapse risk for the SR group was 8% (SE 1.1), whereas the IR and
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F IGURE 1 Overall survival for entire cohort of children with ALL A, and by risk groups B, and event free survival C, D, respectively
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HR groups showed 16.5% (SE 1.2) and 25.9% (SE 2.0) respectively
(Figure S2).
Treatments using standardized regimens or protocols have led to
unprecedented improvements in survival of children with cancer, but
most published regimens are based on therapies developed and deliv-
ered in high-income countries.2 The ALL IC-BFM 2002 trial was
designed to be conducted in countries with inadequate skills and
resources for PCR-based MRD monitoring enabling, however, the strat-
ification and treatment of children with ALL according to a BFM-based
backbone protocol.1 The EFS in our cohort at 5 years is estimated to be
as high as 79%, and OS of 86% at 5 years. These results are clearly
comparable to treatment outcomes presented by several major study
groups or institutions, since over the last two decades the world's lead-
ing leukemia groups have achieved 5-year OS rates of approximately
90% with 2% to 3% deaths resulting from toxicity in childhood ALL.3
A major concern regarding BFM-type chemotherapy for less experi-
enced groups with limited resources was the potential risk of excessive
therapy related mortality (TRM). Indeed, we observed a 4.55% rate of
deaths upon CR, ranging from 1.19% in the SR to 13.77% in the HR
patients. Several study groups from countries with high health expendi-
ture have reported that 2-5% of children with ALL die from other causes
than relapse, and 1-2% of patients die during the induction phase.4
Our study demonstrates a death rate for both induction before
CR1 (1.92%) and during the CR1 phase (4.55%). This may result from
the long duration of the analysis and a change in the standards of sup-
portive therapy. The major leading causes of death, similarly to other
reports, were sepsis, progressive ALL and SCT-related complications.
Infections, both bacterial and fungal, resulted in 24.3% of deaths in
our cohort. In comparison, Möricke et al.5 have reported 69% cases of
death as infection-related. The risk of life-threatening infection
increased during the induction phase.
The cumulative incidence of relapse in our patients after 5 years
for the whole cohort was 15% (SE 0.8), while the individual risk
groups showed 8% (SE 1.1) for SR, 16.5% (SE 1.2) for IR, and 25.9%
(SE 2.0) for HR. These results are nearly identical with those obtained
by the ALL BFM95 study: 16.2% overall (SR-7.8%, SE 1.0; MR-16.8%,
SE 1.2, and HR-38.6%, SE 3.6).6
In conclusion, ALL IC-BFM 2002 proved as a highly effective proto-
col for treatment of children with ALL in Polish pediatric
oncohematology centers. The design of the study allowed us to achieve
outcomes comparable to those reported by study groups in several
countries with high health-related expenditures. The study based on
inexpensive and accessible stratification criteria was highly successful.
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